Click here to view online. Add this email to your safelist.
Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
1 July 2024
AstraZeneca’s Marketing Authorisation Application (MAA) for sipavibart has been accepted under an accelerated assessment procedure by the European Medicines Agency (EMA), for the pre-exposure prophylaxis (prevention) of COVID-19 in immunocompromised patients.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
